Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jul;66(1):39–45. doi: 10.1038/bjc.1992.213

DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients.

R Smaaland 1, J F Abrahamsen 1, A M Svardal 1, K Lote 1, P M Ueland 1
PMCID: PMC1977883  PMID: 1637674

Abstract

DNA cell cycle distribution and glutathione (GSH) content in bone marrow were measured both at daytime and midnight over single 24 h periods in 15 cancer patients. Between patients the S-phase demonstrated a difference from lowest to highest value of 700%, whereas the corresponding difference for the G2/M-phase was nearly 900%. The mean GSH content measured in the bone marrow at the two timepoints was 2.24 +/- 0.21 nmol mg-1 protein, range 0.91-4.19 nmol mg-1 protein. A statistically significant higher fraction of cells in S-phase and G2/M-phase was found at daytime as compared to midnight when excluding the four patients with an abnormal circadian variation in cortisol. No significant temporal variation in total bone marrow GSH content was found, although a weak correlation between S-phase and GSH content was demonstrated (r = 0.42; P less than 0.05). This correlation was strengthened when not including the six patients with an abnormal cortisol pattern (4) and bone marrow infiltration (2) (r = 0.66; P = 0.005). Cells in S-phase demonstrated a positive correlation with cells in G2/M-phase (r = 0.64; P less than 0.0001). A negative correlation was found between GSH content and age (r = 0.53; P less than 0.005). Finally, a statistically significant positive correlation was demonstrated between cortisol and both S-phase and G2/M-phase (r = 0.57; P less than 0.001 and r = 0.38; P less than 0.05, respectively). The present study suggests a possibility of optimising cancer therapy and use of hematopoietic growth factors by determining individual average values and circadian stage dependent variation in bone marrow DNA cell cycle distribution. Furthermore, GSH content in bone marrow may predict this tissue's sensitivity to cytotoxic agents.

Full text

PDF
39

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biaglow J. E., Varnes M. E., Clark E. P., Epp E. R. The role of thiols in cellular response to radiation and drugs. Radiat Res. 1983 Sep;95(3):437–455. [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  3. Bump E. A., Yu N. Y., Brown J. M. The use of drugs which deplete intracellular glutathione in hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):439–442. doi: 10.1016/0360-3016(82)90656-3. [DOI] [PubMed] [Google Scholar]
  4. DeVita V. T. Dose-response is alive and well. J Clin Oncol. 1986 Aug;4(8):1157–1159. doi: 10.1200/JCO.1986.4.8.1157. [DOI] [PubMed] [Google Scholar]
  5. Dean P. N., Jett J. H. Mathematical analysis of DNA distributions derived from flow microfluorometry. J Cell Biol. 1974 Feb;60(2):523–527. doi: 10.1083/jcb.60.2.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Den Boer P. J., Mackenbach P., Grootegoed J. A. Glutathione metabolism in cultured Sertoli cells and spermatogenic cells from hamsters. J Reprod Fertil. 1989 Sep;87(1):391–400. doi: 10.1530/jrf.0.0870391. [DOI] [PubMed] [Google Scholar]
  7. Dethmers J. K., Meister A. Glutathione export by human lymphoid cells: depletion of glutathione by inhibition of its synthesis decreases export and increases sensitivity to irradiation. Proc Natl Acad Sci U S A. 1981 Dec;78(12):7492–7496. doi: 10.1073/pnas.78.12.7492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dusre L., Mimnaugh E. G., Myers C. E., Sinha B. K. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res. 1989 Feb 1;49(3):511–515. [PubMed] [Google Scholar]
  9. Evans W. E. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut. 1988 Jun;56(6):241–248. doi: 10.1007/BF00320282. [DOI] [PubMed] [Google Scholar]
  10. Frankfurt O. S., Seckinger D., Sugarbaker E. V. Intercellular transfer of drug resistance. Cancer Res. 1991 Feb 15;51(4):1190–1195. [PubMed] [Google Scholar]
  11. Friedman H. S., Colvin O. M., Griffith O. W., Lippitz B., Elion G. B., Schold S. C., Jr, Hilton J., Bigner D. D. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. J Natl Cancer Inst. 1989 Apr 5;81(7):524–527. doi: 10.1093/jnci/81.7.524. [DOI] [PubMed] [Google Scholar]
  12. Gray J. W., Dean P. N. Display and analysis of flow cytometric data. Annu Rev Biophys Bioeng. 1980;9:509–539. doi: 10.1146/annurev.bb.09.060180.002453. [DOI] [PubMed] [Google Scholar]
  13. Haus E., Halberg F., Pauly J. E., Cardoso S., Kühl J. F., Sothern R. B., Shiotsuka R. N., Hwang D. S. Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system. Science. 1972 Jul 7;177(4043):80–82. doi: 10.1126/science.177.4043.80. [DOI] [PubMed] [Google Scholar]
  14. Hazelton G. A., Lang C. A. Glutathione contents of tissues in the aging mouse. Biochem J. 1980 Apr 15;188(1):25–30. doi: 10.1042/bj1880025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hrushesky W. J. Circadian timing of cancer chemotherapy. Science. 1985 Apr 5;228(4695):73–75. doi: 10.1126/science.3883493. [DOI] [PubMed] [Google Scholar]
  16. Hryniuk W. M., Figueredo A., Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol. 1987 Dec;14(4 Suppl 4):3–11. [PubMed] [Google Scholar]
  17. Jaeschke H., Wendel A. Diurnal fluctuation and pharmacological alteration of mouse organ glutathione content. Biochem Pharmacol. 1985 Apr 1;34(7):1029–1033. doi: 10.1016/0006-2952(85)90606-9. [DOI] [PubMed] [Google Scholar]
  18. Karp J. E., Broder S. Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res. 1991 Sep 15;51(18):4743–4756. [PubMed] [Google Scholar]
  19. Kavanagh T. J., Martin G. M., Livesey J. C., Rabinovitch P. S. Direct evidence of intercellular sharing of glutathione via metabolic cooperation. J Cell Physiol. 1988 Nov;137(2):353–359. doi: 10.1002/jcp.1041370220. [DOI] [PubMed] [Google Scholar]
  20. Kerr D. J., Lewis C., O'Neil B., Lawson N., Blackie R. G., Newell D. R., Boxall F., Cox J., Rankin E. M., Kaye S. B. The myelotoxicity of carboplatin is influenced by the time of its administration. Hematol Oncol. 1990 Jan-Feb;8(1):59–63. doi: 10.1002/hon.2900080108. [DOI] [PubMed] [Google Scholar]
  21. Lee F. Y., Allalunis-Turner M. J., Siemann D. W. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine. Br J Cancer. 1987 Jul;56(1):33–38. doi: 10.1038/bjc.1987.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lee F. Y. Glutathione diminishes the anti-tumour activity of 4-hydroperoxycyclophosphamide by stabilising its spontaneous breakdown to alkylating metabolites. Br J Cancer. 1991 Jan;63(1):45–50. doi: 10.1038/bjc.1991.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Levi F. A., Hrushesky W. J., Blomquist C. H., Lakatua D. J., Haus E., Halberg F., Kennedy B. J. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982 Mar;42(3):950–955. [PubMed] [Google Scholar]
  24. Li L. Y., Seddon A. P., Meister A., Risley M. S. Spermatogenic cell-somatic cell interactions are required for maintenance of spermatogenic cell glutathione. Biol Reprod. 1989 Feb;40(2):317–331. doi: 10.1095/biolreprod40.2.317. [DOI] [PubMed] [Google Scholar]
  25. Lévi F., Benavides M., Chevelle C., Le Saunier F., Bailleul F., Misset J. L., Regensberg C., Vannetzel J. M., Reinberg A., Mathé G. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol. 1990 Apr;8(4):705–714. doi: 10.1200/JCO.1990.8.4.705. [DOI] [PubMed] [Google Scholar]
  26. MAUER A. M. DIURNAL VARIATION OF PROLIFERATIVE ACTIVITY IN THE HUMAN BONE MARROW. Blood. 1965 Jul;26:1–7. [PubMed] [Google Scholar]
  27. Meister A., Anderson M. E. Glutathione. Annu Rev Biochem. 1983;52:711–760. doi: 10.1146/annurev.bi.52.070183.003431. [DOI] [PubMed] [Google Scholar]
  28. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther. 1991;51(2):155–194. doi: 10.1016/0163-7258(91)90076-x. [DOI] [PubMed] [Google Scholar]
  29. Meister A. Selective modification of glutathione metabolism. Science. 1983 Apr 29;220(4596):472–477. doi: 10.1126/science.6836290. [DOI] [PubMed] [Google Scholar]
  30. Moormeier J. A., Williams S. F., Kaminer L. S., Garner M., Bitran J. D. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Natl Cancer Inst. 1990 Jan 3;82(1):29–34. doi: 10.1093/jnci/82.1.29. [DOI] [PubMed] [Google Scholar]
  31. Ozols R. F., Louie K. G., Plowman J., Behrens B. C., Fine R. L., Dykes D., Hamilton T. C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol. 1987 Jan 1;36(1):147–153. doi: 10.1016/0006-2952(87)90392-3. [DOI] [PubMed] [Google Scholar]
  32. Recombinant GM-CSF in myelosuppression of chemotherapy. N Engl J Med. 1989 Jan 26;320(4):253–254. doi: 10.1056/NEJM198901263200417. [DOI] [PubMed] [Google Scholar]
  33. Russo A., Tochner Z., Phillips T., Carmichael J., DeGraff W., Friedman N., Fisher J., Mitchell J. B. In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to melphalan. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1187–1189. doi: 10.1016/0360-3016(86)90255-5. [DOI] [PubMed] [Google Scholar]
  34. Scheving L. E., Burns E. R., Halberg F., Pauly J. E. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum. Chronobiologia. 1980 Jan-Mar;7(1):33–40. [PubMed] [Google Scholar]
  35. Scheving L. E., Burns E. R., Pauly J. E., Halberg F. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide. Cancer Res. 1980 May;40(5):1511–1515. [PubMed] [Google Scholar]
  36. Scheving L. E., Haus E., Kühl J. F., Pauly J. E., Halberg F., Cardoso S. Close reproduction by different laboratories of characteristics of circadian rhythm in 1-beta-D-arabinofuranosylcytosine tolerance by mice. Cancer Res. 1976 Mar;36(3):1133–1137. [PubMed] [Google Scholar]
  37. Smaaland R., Laerum O. D., Lote K., Sletvold O., Sothern R. B., Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood. 1991 Jun 15;77(12):2603–2611. [PubMed] [Google Scholar]
  38. Smaaland R., Svardal A. M., Lote K., Ueland M., Laerum O. D. Glutathione content in human bone marrow and circadian stage relation to DNA synthesis. J Natl Cancer Inst. 1991 Aug 7;83(15):1092–1098. doi: 10.1093/jnci/83.15.1092. [DOI] [PubMed] [Google Scholar]
  39. Somfai-Relle S., Suzukake K., Vistica B. P., Vistica D. T. Glutathione-conferred resistance to antineoplastics: approaches toward its reduction. Cancer Treat Rev. 1984 Mar;11 (Suppl A):43–54. doi: 10.1016/0305-7372(84)90042-2. [DOI] [PubMed] [Google Scholar]
  40. Somfai-Relle S., Suzukake K., Vistica B. P., Vistica D. T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol. 1984 Feb 1;33(3):485–490. doi: 10.1016/0006-2952(84)90245-4. [DOI] [PubMed] [Google Scholar]
  41. Sothern R. B., Lévi F., Haus E., Halberg F., Hrushesky W. J. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989 Jan 18;81(2):135–145. doi: 10.1093/jnci/81.2.135. [DOI] [PubMed] [Google Scholar]
  42. Svardal A. M., Mansoor M. A., Ueland P. M. Determination of reduced, oxidized, and protein-bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography. Anal Biochem. 1990 Feb 1;184(2):338–346. doi: 10.1016/0003-2697(90)90691-2. [DOI] [PubMed] [Google Scholar]
  43. Tsutsui K., Komuro C., Ono K., Nishidai T., Shibamoto Y., Takahashi M., Abe M. Chemosensitization by buthionine sulfoximine in vivo. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1183–1186. doi: 10.1016/0360-3016(86)90254-3. [DOI] [PubMed] [Google Scholar]
  44. Zbroja R. A., Wass J., Vincent P. C., Young G. A. Fragment filtration: a method for the accurate determination of flow cytometric kinetic data from bone marrow aspirates. Exp Hematol. 1986 Feb;14(2):85–89. [PubMed] [Google Scholar]
  45. von Roemeling R., Hrushesky W. J. Determination of the therapeutic index of floxuridine by its circadian infusion pattern. J Natl Cancer Inst. 1990 Mar 7;82(5):386–393. doi: 10.1093/jnci/82.5.386. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES